Patients with mantle cell lymphoma (MCL) who survive 2 years without disease recurrence or progression live nearly as long as age- and sex-matched individuals in the general population.
Combining a TKI with chemo or an antiangiogenic agent may prolong PFS in advanced NSCLC with certain mutations. The study was published as a preprint and has not yet been peer reviewed.
The second-generation Bruton s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) .